Palliative systemic therapy and overall survival of 1,395 patients with advanced breast cancer - Results from the prospective German TMK cohort study.

[1]  Amy M. Sitapati,et al.  Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. , 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

[2]  H. Tesch,et al.  Adjuvant chemotherapeutic treatment of 1650 patients with early breast cancer in routine care in Germany: data from the prospective TMK cohort study , 2017, Breast Cancer.

[3]  A. Tutt,et al.  3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). , 2017, Breast.

[4]  R. Greil,et al.  Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial. , 2016, The Lancet. Oncology.

[5]  M. de Boer,et al.  In real life, one-quarter of patients with hormone receptor-positive metastatic breast cancer receive chemotherapy as initial palliative therapy: a study of the Southeast Netherlands Breast Cancer Consortium. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  Sung-Bae Kim,et al.  Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. , 2015, The New England journal of medicine.

[7]  E. Winer,et al.  Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  G. Fasola,et al.  Measures of outcome in metastatic breast cancer: insights from a real-world scenario. , 2014, The oncologist.

[9]  J. Mackey,et al.  Presentation and management of docetaxel-related adverse effects in patients with breast cancer , 2014, Cancer management and research.

[10]  J. Signorovitch,et al.  Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2−) breast cancer patients in the United States: 2002–2012 , 2014, Current medical research and opinion.

[11]  I. Tannock,et al.  Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence , 2014, British Journal of Cancer.

[12]  E. Winer,et al.  Use and duration of chemotherapy in patients with metastatic breast cancer according to tumor subtype and line of therapy. , 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

[13]  H. Rugo,et al.  First-line treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positive metastatic breast cancer from registHER. , 2013, The oncologist.

[14]  V. Tjan-Heijnen,et al.  If there is no overall survival benefit in metastatic breast cancer: does it imply lack of efficacy? Taxanes as an example. , 2013, Cancer treatment reviews.

[15]  R. Greil,et al.  Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial. , 2013, The Lancet. Oncology.

[16]  T. Bauknecht,et al.  Taxane-based mono- or combination therapy for managing metastatic breast cancer (MBC) in routine practice: a multinational prospective observational study , 2012, Current medical research and opinion.

[17]  Sung-Bae Kim,et al.  Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. , 2012, The New England journal of medicine.

[18]  Bing Li,et al.  Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. , 2011, American journal of epidemiology.

[19]  J. Bergh,et al.  Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  S. Borstnar,et al.  Triple negative breast cancer – prognostic factors and survival , 2010, Radiology and oncology.

[21]  L. Fallowfield,et al.  Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  M. Stockler,et al.  Third consensus on medical treatment of metastatic breast cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  M. Namer,et al.  Prognostic factors in 1,038 women with metastatic breast cancer. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  U. Albert,et al.  Adherence to Treatment Guidelines in Breast Cancer Care – a Retrospective Analysis of the ‘Organgruppe Mamma der Arbeitsgemeinschaft Gynaekologische Onkologie’ , 2008, Breast Care.

[25]  Tomasz Burzykowski,et al.  Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  E. Winer,et al.  Trastuzumab plus vinorelbine or taxane chemotherapy for HER2‐overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study , 2007, Cancer.

[27]  D. Ghersi,et al.  Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer. , 2003, The Cochrane database of systematic reviews.

[28]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.